专栏名称: 华人抗体
华人抗体协会 (Chinese Antibody Society). 使命和愿景 两个一:第一个“一”是中国抗体药走向世界的桥梁; 第二个“一”是中美乃至全球抗体领域华人交流合作的平台。两个侧重:侧重于治疗性抗体药; 侧重于中国。
目录
相关文章推荐
福昕会员  ·  宴会邀请函定制,仪式感的秘籍! ·  昨天  
福昕会员  ·  宴会邀请函定制,仪式感的秘籍! ·  昨天  
老高电商圈子  ·  “金冠俱乐部都不知道,你干什么电商” ·  2 天前  
老高电商圈子  ·  “金冠俱乐部都不知道,你干什么电商” ·  2 天前  
曹将  ·  朋友下班后,用AI继续工作 ·  2 天前  
51好读  ›  专栏  ›  华人抗体

Antibody Therapeutics 已经发表的25篇双抗论文集锦(英文版)

华人抗体  · 公众号  ·  · 2023-12-15 08:38

正文

请到「今天看啥」查看全文


Antibody Therapeutics , Volume 2, Issue 4, October 2019, Pages 79–87

https://doi.org/10.1093/abt/tbz010


[3] Next-Generation Antibody Therapeutics: Discovery, Development and Beyond: highlights of the third annual conference of the Chinese Antibody Society

Hongyu Zhang, Mi Deng, Fen Pei, Shouye Wang, Mitchell Ho

Antibody Therapeutics , Volume 2, Issue 4, October 2019, Pages 99–107

https://doi.org/10.1093/abt/tbz012


[4] Biology drives the discovery of bispecific antibodies as innovative therapeutics

Siwei Nie, Zhuozhi Wang, Maria Moscoso-Castro, Paul D'Souza, Can Lei, Jianqing Xu, Jijie Gu

Antibody Therapeutics , Volume 3, Issue 1, January 2020, Pages 18–62

https://doi.org/10.1093/abt/tbaa003


[5] Highlights of Antibody Engineering and Therapeutics 2019 in San Diego, USA: Bispecific Antibody Design and Clinical Applications

Yong Zhu, Run Shen, Rui Hao, Shouye Wang, Mitchell Ho

Antibody Therapeutics , Volume 3, Issue 2, April 2020, Pages 146–154

https://doi.org/10.1093/abt/tbaa012


[6] Development of bispecific antibodies in China: overview and prospects

Jing Zhang, Jizu Yi, Pengfei Zhou

Antibody Therapeutics , Volume 3, Issue 2, April 2020, Pages 126–145

https://doi.org/10.1093/abt/tbaa011


[7] Current trends and challenges in the downstream purification of bispecific antibodies

Serene W Chen, Wei Zhang

Antibody Therapeutics , Volume 4, Issue 2, April 2021, Pages 73–88

https://doi.org/10.1093/abt/tbab007


[8] An optimal antitumor response by a novel CEA/CD3 bispecific antibody for colorectal cancers

Ninghai Wang, Harshal Patel, Irene C Schneider, Xin Kai, Avanish K Varshney, Li Zhou

Antibody Therapeutics , Volume 4, Issue 2, April 2021, Pages 90–100

https://doi.org/10.1093/abt/tbab009


[9] Development of a reporter gene method to measure the bioactivity of anti-CD38 × CD3 bispecific antibody

Hui Xiong, Fengyan Luo, Pengfei Zhou, Jizu Yi

Antibody Therapeutics , Volume 4, Issue 4, October 2021, Pages 212–221

https://doi.org/10.1093/abt/tbab022


[10] Biological activity validation of a computationally designed Rituximab/CD3 T cell engager targeting CD20+ cancers with multiple mechanisms of action

Wenyan Cai, Jianbo Dong, Sachith Gallolu Kankanamalage, Allison Titong, Jiadong Shi, Zhejun Jia, Bo Wang, Cai Huang, Jing Zhang, Jun Lin, Steven Z Kan, Shuhua Han, Joe Zhou, Yue Liu

Antibody Therapeutics , Volume 4, Issue 4, October 2021, Pages 228–241

https://doi.org/10.1093/abt/tbab024


[11] Productivity and quality improvement for a symmetric bispecific antibody through the application of intensified perfusion cell culture

Yongjun Qin, Rongmei Ma, Yang Li, Yifeng Li, Gong Chen, Weichang Zhou

Antibody Therapeutics , Volume 5, Issue 2, April 2022, Pages 111–120

https://doi.org/10.1093/abt/tbac009


[12] Development of a T cell-redirecting bispecific antibody targeting B-cell maturation antigen for the suppression of multiple myeloma cell growth







请到「今天看啥」查看全文